AIM Immunotech presents ovarian cancer chemoimmunotherapy data at SITC 2023

AIM ImmunoTech Inc.

Poster presented at SITC 38th Annual Meeting (Nov 1-5, 2023) by UPMC collaborators.
Data on combination intraperitoneal chemoimmunotherapy for recurrent platinum-sensitive ovarian cancer.
Study demonstrates T-cell chemotactic locoregional response per poster title.
Poster available on company's investor website.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.